Efficacy and survival
DISEASE
All of the 12 participants were enrolled for efficacy analysis. Two (16.7%) participants from the 60 mg/mResponse and survival data.Total(60 mg/m(75 mg/m(90 mg/m(Abbreviations: DCR, disease control rate; ORR, overall response rate; OS, overall survival; PFS, progression‐free survival.Waterfall plot of the maximal percentage reduction from baseline of the target lesions.Duration of treatment. Each individual patient treatment time is plotted from time of first dose based on the dose level.(A) Overall survival and (B) Progression‐free survival (Kaplan–Meier curve) of all patients. PFS, progression‐free survival; OS, overall survival.